ZEN-2759
CAS No. 1616400-50-0
ZEN-2759( —— )
Catalog No. M36339 CAS No. 1616400-50-0
ZEN-2759 is a potent BET small molecule inhibitor of BRD4 (BD1), BRD4 (BD2), and BRD4 (BD1BD2).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 86 | In Stock |
|
| 10MG | 131 | In Stock |
|
| 25MG | 220 | In Stock |
|
| 50MG | 323 | In Stock |
|
| 100MG | 451 | In Stock |
|
| 200MG | 639 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameZEN-2759
-
NoteResearch use only, not for human use.
-
Brief DescriptionZEN-2759 is a potent BET small molecule inhibitor of BRD4 (BD1), BRD4 (BD2), and BRD4 (BD1BD2).
-
DescriptionZEN-2759 is a potent BET (Bromodomain and Extra-Terminal Domain) inhibitor, with IC50 values of 0.23, 0.08 and 0.28 μM for BRD4(BD1), BRD4(BD2), and BRD4(BD1BD2), respectively.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
RecptorEpigenetic Reader Domain
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1616400-50-0
-
Formula Weight280.32
-
Molecular FormulaC17H16N2O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (356.74 mM; Ultrasonic )
-
SMILESCC=1C(C2=CN(CC3=CC=CC=C3)C(=O)C=C2)=C(C)ON1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
BRD4 Inhibitor-20
BRD4 Inhibitor-20 is a potent bromodomain protein 4 (BRD4) inhibitor with oral activity, demonstrating antiproliferative effects in cancer cell lines and used in studies of various cancers, including colon cancer.
-
BRD7-IN-1
BRD7-IN-1, a modified derivative of BI7273 (BRD7/9 inhibitor), forms PROTAC VZ185 via linkage to a VHL ligand, demonstrating potent activity against BRD7/9 with DC50 values of 4.5 and 1.8 nM, respectively .
-
BAZ1A-IN-1
BAZ1A-IN-1 is a potent BAZ1A inhibitor with the KD value of 0.52 μM for the BAZ1A bromodomain. BAZ1A-IN-1 shows good anti-survival activity against cancer cell lines with high BAZ1A expression, but weak or no activity against cancer cells with low BAZ1A expression.
Cart
sales@molnova.com